New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Iqirvo (elafibranor) Tablets

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

IQIRVO is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.

IQIRVO is not recommended for patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Brand Name: Iqirvo
Active Ingredient: elafibranor
Dosage Forms And Strengths: Tablets: 80 mg
Manufacturer: IPSEN BIOPHARM LTD
FDA-approved use on approval date: Treatment of primary biliary cholangitis in combination with ursodeoxycholic acid
Price: On Request

Do you need this medicine in India?

To help you get this medicine – Iqirvo (elafibranor), a prescription from the Registered Medical Practitioner (RMP) is required. Contact Mr. Tarun at 9891296838 via Call or WhatsApp for availability in India.

Category
Iqirvo (elafibranor) cost Price Delhi India
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Note: Notice for Sourcing Inquiries

Description

Elafibranor is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.

In June 2024, the US Food and Drug Administration (FDA) granted accelerated approval to elafibranor. The FDA considers it to be a first-in-class medication.

IQIRVO (elafibranor) tablets, for oral use Initial U.S. Approval: 2024

See full prescribing information: Click Here

Get Access To Iqirvo (elafibranor) Tablets In India on request

Brand Name “Iqirvo” or Generic Name “elafibranor” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or  you can call at 9891296838 or WhatsApp at 9891296838

Related Products

Related products